by jmanor | Nov 29, 2021 | White Papers
This issue brief reviews the evidence-base to assess the impact HR 5376 on innovation into antivirals and patient health. A large academic literature estimates the effect of future drug revenues on R&D spending and finds that on average that a 1 percent reduction...
by jmanor | Sep 14, 2021 | Uncategorized, White Papers
This issue brief reviews the evidence on the impact of price controls on biopharmaceutical innovation and calibrates what this evidence implies for recent price control proposals in the US. A large academic literature estimates the effect of future drug revenues on...
by susuguo | Jul 24, 2021 | White Papers
The health costs of in-person schooling during the pandemic, if any, fall primarily on the families of students, largely owing to the fact that students significantly outnumber teach- ers. Data from North Carolina, Wisconsin, Australia, England, and Israel covering...
by susuguo | Jun 9, 2021 | White Papers
The “shutdown” economy of April 2020 is compared to a normally functioning economy both in terms of market and nonmarket activities. Three novel methods and data indicate that a full shutdown of “nonessential” activities puts market production about 25 % below normal...
by Matt Fey | Apr 26, 2021 | Uncategorized, White Papers
The spread of COVID-19 in the United States has prompted extraordinary, although often untested, steps by individuals and institutions to limit infections. Schools, restaurants, entertainment venues, and many other places of business were required to close under the...
by Matt Fey | Apr 26, 2021 | Uncategorized, White Papers
Employer-sponsored health insurance (ESI) is over a trillion-dollar market with about 160 million Americans (a majority) participating as plan members, of which about 80 million are policy holders. The policies are valuable not only to employers and employees, but...
